Chen, Jinluan http://orcid.org/0000-0001-6800-9771
van der Duin, Daniel
Campos-Obando, Natalia
Ikram, Mohammad Arfan
Nijsten, Tamar E. C.
Uitterlinden, André G.
Zillikens, Maria Carola
Clinical trials referenced in this document:
Documents that mention this clinical trial
Risk of cancer after ST-segment-elevation myocardial infarction
https://doi.org/10.1007/s10654-023-00984-8
Serum 25-hydroxyvitamin D3 is associated with advanced glycation end products (AGEs) measured as skin autofluorescence: The Rotterdam Study
https://doi.org/10.1007/s10654-018-0444-2
Dietary protein intake and all-cause and cause-specific mortality: results from the Rotterdam Study and a meta-analysis of prospective cohort studies
https://doi.org/10.1007/s10654-020-00607-6
Advanced glycation end products measured by skin autofluorescence and subclinical cardiovascular disease: the Rotterdam Study
https://doi.org/10.1186/s12933-023-02052-7
Funding for this research was provided by:
Erasmus Medisch Centrum
Erasmus Universiteit Rotterdam
Netherlands Organization for the Health Research and Development
the Research Institute for Diseases in the Elderly
the Netherlands Genomics Initiative
the Ministry of Education, Culture and Science
the Ministry for Health, Welfare and Sports
European Commission
the Municipality of Rotterdam
DSM Nutritional Products AG, Kaiseraugst, Switzerland
China Scholarship Council (No. 201606170110)
Jaap Schouten Foundation, Rotterdam, The Netherlands (Not applicable)
Article History
Received: 24 May 2018
Accepted: 14 September 2018
First Online: 25 September 2018
Compliance with ethical standards
:
: DSM Nutritional Products AG, Kaiseraugst, Switzerland provided funding for the analyses of serum vitamin D. It has no influence in the study design, collection, analysis, interpretation of data, writing of the report and in the decision to submit the article. There are no other potential conflicts of interest in this work.
: The Rotterdam Study was approved by the institutional review board (Medical ethics Committee) of the Erasmus Medical Center (Registration Number MEC 02.1015) and by the review board of The Netherlands Ministry of health, Welfare and Sports (Population Screening Act WBO, License Number 1071272-159521-PG). The Rotterdam Study has been registered in the Netherlands National Trial Register and the WHO International Clinical Trials Registry Platform.
: “All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.” The Rotterdam Study was approved by the institutional review board (Medical Ethics Committee) of Erasmus Medical Center.
: Informed consent was obtained from all individual participants included in the study.